Colorectal Cancer (CRC) Clinical Trial
Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01450319 -
A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
|
Phase 2 | |
| Recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02903914 -
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03253185 -
A Study of SC-007 in Subjects With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00851045 -
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04622423 -
Advanced Therapies for Liver Metastases
|
||
| Active, not recruiting |
NCT02955940 -
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
|
Phase 2 | |
| Completed |
NCT02327078 -
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
|
Phase 1/Phase 2 | |
| Completed |
NCT03314935 -
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05379985 -
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
|
Phase 1 | |
| Recruiting |
NCT05648955 -
Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment
|
Early Phase 1 | |
| Recruiting |
NCT05706129 -
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02646748 -
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT02005913 -
A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence
|
N/A | |
| Recruiting |
NCT04256707 -
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04792684 -
Collection of Samples USOPTIVAL Study
|
||
| Completed |
NCT00483080 -
Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
|
Phase 2 |